PRLD

NASDAQStock

Prelude Therapeutics Incorporated

$3.33-0.04 (-1.34%)

52-Week Range

$0.61

$3.98

Key Stats

Market Cap

—

P/E Ratio

—

Dividend Yield

—

Beta

0.87

Volume

221.1K

Avg Volume

396.6K

Performance

+50.45%

+73.71%

+203.60%

YTD

+23.44%

+352.47%

-48.31%

-94.17%

Price Chart

ETF Exposure

PRLD is held by 9 ETFs

ETF	Fund Name	Weight	Shares	Market Value	Fund AUM	Expense Ratio
AVSC	Avantis U.S. Small Cap Equity ETF	0.00%	10,294	$35K	$2.36B	0.25%
VXF	Vanguard Extended Market ETF	0.00%	285,294	$528K	$84.10B	0.05%
DCOR	Dimensional - US Core Equity 1 ETF	0.00%	1,348	$5K	$2.68B	0.14%
VCNS.TO	Vanguard Conservative ETF Portfolio	0.00%	46	$115	$820.6M	0.25%
VEQT.TO	Vanguard All-Equity ETF Portfolio	0.00%	1,644	$4K	$12.17B	0.24%
VRIF.TO	Vanguard Retirement Income ETF Portfolio	0.00%	7	$19	$337.7M	0.32%
VTI	Vanguard Total Stock Market ETF	0.00%	936,001	$1.7M	$2.10T	0.03%
VUN.TO	Vanguard U.S. Total Market Index ETF	0.00%	4,923	$12K	$15.33B	0.17%
VUS.TO	Vanguard U.S. Total Market Index ETF (CAD-hedged)	0.00%	424	$1K	$1.29B	0.17%

About PRLD ETF Exposure

Prelude Therapeutics Incorporated (PRLD) is held by 9 exchange-traded funds, making it one of the stocks with significant ETF exposure. The stock currently trades at $3.33. Investors can gain exposure to PRLD through a variety of ETFs with different expense ratios, investment strategies, and portfolio weightings. The table above shows all ETFs that currently hold PRLD, sorted by portfolio weight.